pdf   xlsx method abbreviations

mML - 1st line (L1), nivolumab alone versus ipilimumab alone, meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.63 [0.48, 0.82]< 10%1 study (1/-)100.0 %NAnot evaluable crucial-
deaths (OS) (extension) 0.63 [0.52, 0.76]< 10%1 study (1/-)100.0 %NAnot evaluable important-
PFS (extension) 0.53 [0.44, 0.64]< 10%1 study (1/-)100.0 %NAnot evaluable important-
progression or deaths (PFS) 0.57 [0.43, 0.76]< 10%1 study (1/-)100.0 %NAnot evaluable important-
objective responses (ORR) 3.40 [2.02, 5.72]> 10%1 study (1/-)100.0 %NAnot evaluable non important-
objective responses (ORR) (extension) 3.54 [2.46, 5.10]> 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

TRAE (any grade) 1.01 [0.64, 1.59]< 10%1 study (1/-)48.7 %NAnot evaluable non important-
TRAE (grade 3-4) 0.71 [0.49, 1.03]< 10%1 study (1/-)96.5 %NAnot evaluable non important-
TRAE leading to death (grade 5) 0.99 [0.02, 50.24]< 10%1 study (1/-)50.1 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 0.72 [0.45, 1.13]< 10%1 study (1/-)92.2 %NAnot evaluable non important-
TRAE leading to discontinuation (grade 3-4) 0.52 [0.31, 0.88]< 10%1 study (1/-)99.3 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Abdominal pain TRAE (grade 3-4) 0.25 [0.01, 5.50]< 10%1 study (1/-)80.8 %NAnot evaluable non important-
Adrenal insufficiency TRAE (grade 3-4) 1.99 [0.18, 22.10]< 10%1 study (1/-)28.8 %NAnot evaluable non important-
Arthralgia TRAE (grade 3-4) 1.99 [0.07, 59.55]< 10%1 study (1/-)34.8 %NAnot evaluable non important-
Asthenia TRAE (grade 3-4) 0.50 [0.04, 5.49]< 10%1 study (1/-)71.5 %NAnot evaluable non important-
Colitis TRAE (grade 3-4) 0.12 [0.03, 0.39]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
Cough TRAE (grade 3-4) 3.99 [0.18, 88.92]< 10%1 study (1/-)19.4 %NAnot evaluable non important-
Decreased appetite TRAE (grade 3-4) 0.50 [0.02, 14.84]< 10%1 study (1/-)65.5 %NAnot evaluable non important-
Diarrhoea TRAE (grade 3-4) 0.48 [0.21, 1.09]< 10%1 study (1/-)96.0 %NAnot evaluable non important-
Dry skin TRAE (grade 3-4) 0.99 [0.02, 50.24]< 10%1 study (1/-)50.1 %NAnot evaluable non important-
Dyspnoea TRAE (grade 3-4) 1.99 [0.07, 59.55]< 10%1 study (1/-)34.8 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 0.99 [0.20, 4.96]< 10%1 study (1/-)50.3 %NAnot evaluable non important-
Headache TRAE (grade 3-4) 0.50 [0.02, 14.84]< 10%1 study (1/-)65.5 %NAnot evaluable non important-
Hepatitis TRAE (grade 3-4) 0.99 [0.02, 50.24]< 10%1 study (1/-)50.1 %NAnot evaluable non important-
Hyperthyroidism TRAE (grade 3-4) 0.99 [0.02, 50.24]< 10%1 study (1/-)50.1 %NAnot evaluable non important-
Hypophysitis TRAE (grade 3-4) 0.20 [0.02, 1.69]< 10%1 study (1/-)93.0 %NAnot evaluable non important-
Hypothyroidism TRAE (grade 3-4) 0.99 [0.02, 50.24]< 10%1 study (1/-)50.1 %NAnot evaluable non important-
Increase AST TRAE (grade 3-4) 1.50 [0.25, 9.01]< 10%1 study (1/-)33.1 %NAnot evaluable non important-
Increased ALT TRAE (grade 3-4) 0.79 [0.21, 2.98]< 10%1 study (1/-)63.5 %NAnot evaluable non important-
Increased lipase level TRAE (grade 3-4) 1.17 [0.53, 2.56]< 10%1 study (1/-)35.1 %NAnot evaluable non important-
Maculopapular rash TRAE (grade 3-4) 1.99 [0.18, 22.10]< 10%1 study (1/-)28.8 %NAnot evaluable non important-
Myalgia TRAE (grade 3-4) 1.99 [0.07, 59.55]< 10%1 study (1/-)34.8 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 0.25 [0.01, 5.50]< 10%1 study (1/-)80.8 %NAnot evaluable non important-
Pneumonitis TRAE (grade 3-4) 0.99 [0.06, 15.96]< 10%1 study (1/-)50.2 %NAnot evaluable non important-
Pruritic rash TRAE (grade 3-4) 0.99 [0.02, 50.24]< 10%1 study (1/-)50.1 %NAnot evaluable non important-
Pruritus TRAE (grade 3-4) 0.99 [0.06, 15.96]< 10%1 study (1/-)50.2 %NAnot evaluable non important-
Pyrexia TRAE (grade 3-4) 0.50 [0.02, 14.84]< 10%1 study (1/-)65.5 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 0.20 [0.02, 1.69]< 10%1 study (1/-)93.0 %NAnot evaluable non important-
Thyroiditis TRAE (grade 3-4) 0.99 [0.02, 50.24]< 10%1 study (1/-)50.1 %NAnot evaluable non important-
Vitiligo TRAE (grade 3-4) 1.99 [0.07, 59.55]< 10%1 study (1/-)34.8 %NAnot evaluable non important-
Vomiting TRAE (grade 3-4) 0.99 [0.06, 15.96]< 10%1 study (1/-)50.2 %NAnot evaluable non important-
Weight decreased TRAE (grade 3-4) 0.50 [0.02, 14.84]< 10%1 study (1/-)65.5 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons